Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 7608693

High affinity human antibodies to human IL-4 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7605237

High affinity human antibodies to human IL-4 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7582298

High affinity antibodies to human IL-6 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7576065

Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concu

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 18 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 13 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7572893

IL-1 antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 11 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7557084

IL-18 specific polypeptides and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7534868

Human antibodies to human delta like ligand 4

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7534604

Fusion polypeptides capable of activating receptors

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7531172

Methods of treating diseases with a VEGF antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7531173

Ophthalmic composition of a VEGF antagonist

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 12 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 07 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7524499

Modified chimeric polypeptides with improved pharmacokinetic properties

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 28 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7521211

IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7521049

Use of VEGF inhibitors for treatment of eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7488806

Human antibodies to human delta like ligand 4

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7482002

Method of administering and using VEGF inhibitors for the treatment of prostate cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479272

Method of administering and using VEGF inhibitors for the treatment of breast cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479275

Method of administering and using VEGF inhibitors for the treatment of colorectal cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479274

Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinom

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7479273

Method of administering and using VEGF inhibitors for the treatment of renal cell cancer

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7459426

Methods of using IL-1 antagonists to treat autoinflammatory disease

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 02 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7449182

Therapeutic combination of a VEGF antagonist and anti-hypertensive agent

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 11 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 06 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7417134

IL-1 receptor based cytokine traps and method of using

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 26 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 21 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7410781

IL-4/IL-13 specific polypeptides and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 12 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 07 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7399612

VEGF-binding fusion proteins and nucleic acids encoding the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 15 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

granted